Viread can now be prescribed, in combination with other antiretrovirals, for children aged 2 years and older with HIV-1 infection. In addition, it may be used to treat chronic hepatitis B in adolescents aged 12 years and older with compensated liver disease, evidence of active viral replication, persistently elevated ALT levels and histological evidence of active inflammation and/or fibrosis.
New tablets and granules now available
In order to support dosing in children aged 6–12 years, Gilead has launched three new strengths of Viread tablets: 123mg (for children 17–22kg); 163mg (for children 22–28kg); and 204mg (for children 28–55kg). An oral granule formulation is also now available for children aged 2–6 years and for patients of all ages when a solid dosage form is not appropriate. The granules should be mixed with soft food (eg, yoghurt) before being taken.
Discontinue if renal dysfunction develops in children
Tenofovir is not recommended for use in children with renal impairment and should be discontinued in children who develop renal impairment.